Close
Help




JOURNAL

Clinical Medicine Reviews in Therapeutics

Safety and Efficacy of Ceftaroline Fosamil in the Management of Community-Acquired Bacterial Pneumonia

Submit a Paper


Clinical Medicine Reviews in Therapeutics 2014:6 1-6

Review

Published on 16 Mar 2014

DOI: 10.4137/CMRT.S9346


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics

Abstract

Ceftaroline fosamil is a new fifth-generation cephalosporin indicated for the treatment of community-acquired bacterial pneumonia (CABP). It possesses antimicrobial effects against both Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), but not against anaerobes. Organisms covered by this novel agent that are commonly associated with CABP are Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and Klebsiella pneumoniae; however, ceftaroline fosamil lacks antimicrobial activity against Pseudomonas and Acinetobacter species. FOCUS 1 and FOCUS 2 clinical trials evaluated the use of ceftaroline fosamil in the treatment of CABP as compared to ceftriaxone. These non-inferiority trials provided evidence that ceftaroline fosamil is as effective and safe as ceftriaxone in the treatment of CABP. As its role in the treatment has not been well established, ceftaroline fosamil should be reserved for patients at high risk for multidrug-resistant organisms (MDROs). This review summarizes ceftaroline fosamil's pharmacokinetic and pharmacodynamic profile, clinical efficacy and safety, and place in therapy for the treatment and management of CABP.



Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)


Sharing


What Your Colleagues Say About Libertas Academica
My publishing experience in Clinical Medicine Insights: Therapeutics was great and enjoyable.  The whole process of publication was fast and smooth.  I highly recommend this journal.  Thank you very much and keep up the good work.
Dr Nada Zaki (Universiti Sains Malaysia, Malaysia)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube